Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from GoHealth ( (GOCO) ).
On August 19, 2025, GoHealth, Inc. appointed Mark Weinsten and Bao Truong as new directors to its Board. Weinsten, a managing director at BRG Corporate Finance, will serve as a Class II director until 2028, receiving a monthly cash retainer. Truong, a senior managing director at Centerbridge Partners, will serve as a Class III director until 2026 and will not receive compensation due to his employment with Centerbridge. Both appointments are part of the Stockholders Agreement with Centerbridge. Concurrently, directors Jeremy W. Gelber and Abhiraj Modi resigned from the Board, with their departures not due to any disagreements with the company.
The most recent analyst rating on (GOCO) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on GoHealth stock, see the GOCO Stock Forecast page.
Spark’s Take on GOCO Stock
According to Spark, TipRanks’ AI Analyst, GOCO is a Neutral.
GoHealth’s overall stock score reflects significant financial challenges, including high leverage and liquidity issues, which weigh heavily on the score. While technical analysis and earnings call insights provide some positive signals, the negative valuation and financial performance are the most impactful factors.
To see Spark’s full report on GOCO stock, click here.
More about GoHealth
Average Trading Volume: 54,159
Technical Sentiment Signal: Sell
Current Market Cap: $133.2M
Find detailed analytics on GOCO stock on TipRanks’ Stock Analysis page.